Cargando…

NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses

Exome sequencing provides unprecedented insights into cancer biology and pharmacological response. Here we assess these two parameters for the NCI-60, which is among the richest genomic and pharmacological publicly available cancer cell line databases. Homozygous genetic variants that putatively aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinhold, William C., Varma, Sudhir, Sousa, Fabricio, Sunshine, Margot, Abaan, Ogan D., Davis, Sean R., Reinhold, Spencer W., Kohn, Kurt W., Morris, Joel, Meltzer, Paul S., Doroshow, James H., Pommier, Yves
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102467/
https://www.ncbi.nlm.nih.gov/pubmed/25032700
http://dx.doi.org/10.1371/journal.pone.0101670
_version_ 1782481042975752192
author Reinhold, William C.
Varma, Sudhir
Sousa, Fabricio
Sunshine, Margot
Abaan, Ogan D.
Davis, Sean R.
Reinhold, Spencer W.
Kohn, Kurt W.
Morris, Joel
Meltzer, Paul S.
Doroshow, James H.
Pommier, Yves
author_facet Reinhold, William C.
Varma, Sudhir
Sousa, Fabricio
Sunshine, Margot
Abaan, Ogan D.
Davis, Sean R.
Reinhold, Spencer W.
Kohn, Kurt W.
Morris, Joel
Meltzer, Paul S.
Doroshow, James H.
Pommier, Yves
author_sort Reinhold, William C.
collection PubMed
description Exome sequencing provides unprecedented insights into cancer biology and pharmacological response. Here we assess these two parameters for the NCI-60, which is among the richest genomic and pharmacological publicly available cancer cell line databases. Homozygous genetic variants that putatively affect protein function were identified in 1,199 genes (approximately 6% of all genes). Variants that are either enriched or depleted compared to non-cancerous genomes, and thus may be influential in cancer progression and differential drug response were identified for 2,546 genes. Potential gene knockouts are made available. Assessment of cell line response to 19,940 compounds, including 110 FDA-approved drugs, reveals ≈80-fold range in resistance versus sensitivity response across cell lines. 103,422 gene variants were significantly correlated with at least one compound (at p<0.0002). These include genes of known pharmacological importance such as IGF1R, BRAF, RAD52, MTOR, STAT2 and TSC2 as well as a large number of candidate genes such as NOM1, TLL2, and XDH. We introduce two new web-based CellMiner applications that enable exploration of variant-to-compound relationships for a broad range of researchers, especially those without bioinformatics support. The first tool, “Genetic variant versus drug visualization”, provides a visualization of significant correlations between drug activity-gene variant combinations. Examples are given for the known vemurafenib-BRAF, and novel ifosfamide-RAD52 pairings. The second, “Genetic variant summation” allows an assessment of cumulative genetic variations for up to 150 combined genes together; and is designed to identify the variant burden for molecular pathways or functional grouping of genes. An example of its use is provided for the EGFR-ERBB2 pathway gene variant data and the identification of correlated EGFR, ERBB2, MTOR, BRAF, MEK and ERK inhibitors. The new tools are implemented as an updated web-based CellMiner version, for which the present publication serves as a compendium.
format Online
Article
Text
id pubmed-4102467
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-41024672014-07-21 NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses Reinhold, William C. Varma, Sudhir Sousa, Fabricio Sunshine, Margot Abaan, Ogan D. Davis, Sean R. Reinhold, Spencer W. Kohn, Kurt W. Morris, Joel Meltzer, Paul S. Doroshow, James H. Pommier, Yves PLoS One Research Article Exome sequencing provides unprecedented insights into cancer biology and pharmacological response. Here we assess these two parameters for the NCI-60, which is among the richest genomic and pharmacological publicly available cancer cell line databases. Homozygous genetic variants that putatively affect protein function were identified in 1,199 genes (approximately 6% of all genes). Variants that are either enriched or depleted compared to non-cancerous genomes, and thus may be influential in cancer progression and differential drug response were identified for 2,546 genes. Potential gene knockouts are made available. Assessment of cell line response to 19,940 compounds, including 110 FDA-approved drugs, reveals ≈80-fold range in resistance versus sensitivity response across cell lines. 103,422 gene variants were significantly correlated with at least one compound (at p<0.0002). These include genes of known pharmacological importance such as IGF1R, BRAF, RAD52, MTOR, STAT2 and TSC2 as well as a large number of candidate genes such as NOM1, TLL2, and XDH. We introduce two new web-based CellMiner applications that enable exploration of variant-to-compound relationships for a broad range of researchers, especially those without bioinformatics support. The first tool, “Genetic variant versus drug visualization”, provides a visualization of significant correlations between drug activity-gene variant combinations. Examples are given for the known vemurafenib-BRAF, and novel ifosfamide-RAD52 pairings. The second, “Genetic variant summation” allows an assessment of cumulative genetic variations for up to 150 combined genes together; and is designed to identify the variant burden for molecular pathways or functional grouping of genes. An example of its use is provided for the EGFR-ERBB2 pathway gene variant data and the identification of correlated EGFR, ERBB2, MTOR, BRAF, MEK and ERK inhibitors. The new tools are implemented as an updated web-based CellMiner version, for which the present publication serves as a compendium. Public Library of Science 2014-07-17 /pmc/articles/PMC4102467/ /pubmed/25032700 http://dx.doi.org/10.1371/journal.pone.0101670 Text en © 2014 Reinhold et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Reinhold, William C.
Varma, Sudhir
Sousa, Fabricio
Sunshine, Margot
Abaan, Ogan D.
Davis, Sean R.
Reinhold, Spencer W.
Kohn, Kurt W.
Morris, Joel
Meltzer, Paul S.
Doroshow, James H.
Pommier, Yves
NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
title NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
title_full NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
title_fullStr NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
title_full_unstemmed NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
title_short NCI-60 Whole Exome Sequencing and Pharmacological CellMiner Analyses
title_sort nci-60 whole exome sequencing and pharmacological cellminer analyses
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4102467/
https://www.ncbi.nlm.nih.gov/pubmed/25032700
http://dx.doi.org/10.1371/journal.pone.0101670
work_keys_str_mv AT reinholdwilliamc nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT varmasudhir nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT sousafabricio nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT sunshinemargot nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT abaanogand nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT davisseanr nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT reinholdspencerw nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT kohnkurtw nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT morrisjoel nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT meltzerpauls nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT doroshowjamesh nci60wholeexomesequencingandpharmacologicalcellmineranalyses
AT pommieryves nci60wholeexomesequencingandpharmacologicalcellmineranalyses